Boehringer Ingelheim: Metalyse® successfully approved in China for the treatment of acute ischemic stroke Go back »

2025-06-06 | All chapters

Boehringer Ingelheim: Metalyse® successfully approved in China for the treatment of acute ischemic stroke

In May, Boehringer Ingelheim's innovative thrombolytic drug, Metalyse® (tenecteplase)  has received approval from the National Medical Products Administration of China for the treatment of acute ischemic stroke (AIS) within 4.5 hours of symptom onset. The approval of the innovative thrombolytic therapy marks a significant milestone—not only providing Chinese patients with a new treatment option, but also heralding a new chapter in stroke care in China.

Source: Boehringer Ingelheim